Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yolanda Blanco

Showing results (131-140 of 156) with videos related to

Pageof 16
Sort By:
Brain : a Journal of Neurology|February 18, 2015
Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromesEster Cantó, Mar Tintoré, Luisa M Villar, et al.
Journal of Clinical Medicine|December 9, 2023
Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre StudyAgustín Sancho-Saldaña, Anna Gil-Sánchez, Cristina González-Mingot, et al.
Therapeutic Advances in Neurological Disorders|November 11, 2024
The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort studyDavid Levitz, Yi Chao Foong, Paul Sanfilippo, et al.
Journal of Neurology|December 22, 2023
Predicting disease severity in multiple sclerosis using multimodal data and machine learningMagi Andorra, Ana Freire, Irati Zubizarreta, et al.
The Lancet. Neurology|March 21, 2026
Complications, outcomes, and implications of a prolonged vegetative state in anti-NMDA receptor encephalitis: a retrospective international cohort studyMar Guasp, Mateus Mistieri Simabukuro, Guillermo Muñoz-Sánchez, et al.
Brain : a Journal of Neurology|August 5, 2024
Serum biomarkers at disease onset for personalized therapy in multiple sclerosisEnric Monreal, José Ignacio Fernández-Velasco, Roberto Álvarez-Lafuente, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 1, 2024
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosisIzanne Roos, Sifat Sharmin, Charles Malpas, et al.
Brain Communications|September 5, 2025
Persistent progression independent of relapse activity in multiple sclerosisChao Zhu, Zhen Zhou, Tomas Kalincik, et al.
Brain : a Journal of Neurology|August 4, 2025
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosisTomas Kalincik, Sifat Sharmin, Izanne Roos, et al.
Frontiers in Neurology|January 8, 2024
Predictors of treatment switching in the Big Multiple Sclerosis Data NetworkTim Spelman, Melinda Magyari, Helmut Butzkueven, et al.
Pageof 16

Showing results (131-140 of 156) with videos related to

Sort By:
Pageof 16
Brain : a Journal of Neurology|February 18, 2015
Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromesEster Cantó, Mar Tintoré, Luisa M Villar, et al.
Journal of Clinical Medicine|December 9, 2023
Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre StudyAgustín Sancho-Saldaña, Anna Gil-Sánchez, Cristina González-Mingot, et al.
Therapeutic Advances in Neurological Disorders|November 11, 2024
The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort studyDavid Levitz, Yi Chao Foong, Paul Sanfilippo, et al.
Journal of Neurology|December 22, 2023
Predicting disease severity in multiple sclerosis using multimodal data and machine learningMagi Andorra, Ana Freire, Irati Zubizarreta, et al.
The Lancet. Neurology|March 21, 2026
Complications, outcomes, and implications of a prolonged vegetative state in anti-NMDA receptor encephalitis: a retrospective international cohort studyMar Guasp, Mateus Mistieri Simabukuro, Guillermo Muñoz-Sánchez, et al.
Brain : a Journal of Neurology|August 5, 2024
Serum biomarkers at disease onset for personalized therapy in multiple sclerosisEnric Monreal, José Ignacio Fernández-Velasco, Roberto Álvarez-Lafuente, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 1, 2024
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosisIzanne Roos, Sifat Sharmin, Charles Malpas, et al.
Brain Communications|September 5, 2025
Persistent progression independent of relapse activity in multiple sclerosisChao Zhu, Zhen Zhou, Tomas Kalincik, et al.
Brain : a Journal of Neurology|August 4, 2025
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosisTomas Kalincik, Sifat Sharmin, Izanne Roos, et al.
Frontiers in Neurology|January 8, 2024
Predictors of treatment switching in the Big Multiple Sclerosis Data NetworkTim Spelman, Melinda Magyari, Helmut Butzkueven, et al.
Pageof 16